Zuhal Keskin Yildirim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zuhal Keskin Yildirim has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Başak Adaklı Aksoy
Department of Pediatric Hematology and Oncology, Altınbaş University- Medical Park Bahçelievler Hospital, Pediatric Bone Marrow Transplantation Unit, Istanbul, Turkey
2 shared publications - Gamzenur Yalçınkaya
Samsun Üniversitesi Tıp Fakültesi, Çocuk Hastalıkları Anabilim Dalı, Samsun, Türkiye
2 shared publications - Mustafa Büyükavcı
SAKARYA ÜNİVERSİTESİ TIP FAKÜLTESİ ÇOCUK HEMATOLOJİSİ VE ONKOLOJİSİ BD
2 shared publications - Rejin Kebudi
Department of Pediatric Hematology and Oncology, Oncology Institute, Istanbul University, 34093 Istanbul, Türkiye
2 shared publications - Şeyma Karatekin
Division of Social Pediatrics, Department of Child and Disease, Samsun University Faculty of Medicine, Samsun, Türkiye
2 shared publications - Şeyma Koca
Samsun Üniversitesi Tıp Fakültesi, Çocuk Hastalıkları Anabilim Dalı, Samsun, Türkiye
2 shared publications
Latest Publications
- 12 October 2026
- Published by Bilimsel Tip Publishing House in Journal of Pediatric Infection
- Vol. 20 (3) , e212-e216
Hemoglobin–Hematocrit Mismatch in MycoplasmaInduced Cold Agglutinin Disease: Case Series
- 12 October 2026
- Published by Bilimsel Tip Publishing House in Journal of Pediatric Infection
- Vol. 20 (3) , e212-e216
Hemoglobin–Hematocrit Mismatch in MycoplasmaInduced Cold Agglutinin Disease: Case Series
- 12 October 2026
- Published by Bilimsel Tip Publishing House in Journal of Pediatric Infection
- Vol. 20 (3) , 205-209
Mikoplazma Kaynaklı Soğuk Aglütinin Hastalığında Hemoglobin-Hematokrit Uyumsuzluğu: Vaka Serisi
- 12 October 2026
- Published by Bilimsel Tip Publishing House in Journal of Pediatric Infection
- Vol. 20 (3) , 205-209
Mikoplazma Kaynaklı Soğuk Aglütinin Hastalığında Hemoglobin-Hematokrit Uyumsuzluğu: Vaka Serisi
- Open Access
- 25 September 2026
- Published by Springer Nature in Annals of Hematology
Real-world outcomes of children with first relapsed acute lymphoblastic leukemia treated according to the ALL-IC REL 2016 guideline in Türkiye
- 25 September 2026
- Published by Springer Nature in Annals of Hematology
Open AccessReal-world outcomes of children with first relapsed acute lymphoblastic leukemia treated according to the ALL-IC REL 2016 guideline in Türkiye
- Open Access
- 20 February 2025
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 17 (4) , 402-409
Evaluation of Heavy Menstrual Bleeding in Adolescents
Heavy menstrual bleeding (HMB) in adolescents often manifests as "excessive bleeding" and may result in acute anemia requiring emergency treatment. This study aimed to evaluate the diagnostic and management options for adolescents with HMB. Retrospective data were collected from the patients' medical records. Adolescents were classified based on the degree of anemia: Group 1 included patients with hemoglobin (Hb) levels of <8 g/dL; Group 2, Hb levels of 8-10 g/dL; Group 3, Hb levels of 10-12 g/dL; and Group 4, Hb levels of ≥12 g/dL. Admission and follow-up characteristics were compared across groups. The cohort consisted of 122 adolescents with a mean age of 13.7 ± 1.9 years, 42.7% of whom experienced menstrual irregularity within 2 years of menarche. The mean duration of bleeding was 16 days (range: 10-30 days). Anovulation was identified in 57.8% of patients. Polycystic ovary syndrome was diagnosed in 32 (25%) adolescents, hypothyroidism in 6 (4.7%), uterine structural anomalies in 3 (2.3%), and hyperprolactinemia in 3 (2.3%), 2 of whom had microprolactinoma. One adolescent was diagnosed with von Willebrand disease following a hematological evaluation. Primary care providers must understand normal menstrual cycle patterns and be adept at identifying HMB. Early recognition of the underlying etiology in adolescents facilitates timely diagnosis, helping to prevent severe anemia and hospitalization.
- 20 February 2025
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 17 (4) , 402-409
Open AccessEvaluation of Heavy Menstrual Bleeding in Adolescents
Heavy menstrual bleeding (HMB) in adolescents often manifests as "excessive bleeding" and may result in acute anemia requiring emergency treatment. This study aimed to evaluate the diagnostic and management options for adolescents with HMB. Retrospective data were collected from the patients' medical records. Adolescents were classified based on the degree of anemia: Group 1 included patients with hemoglobin (Hb) levels of <8 g/dL; Group 2, Hb levels of 8-10 g/dL; Group 3, Hb levels of 10-12 g/dL; and Group 4, Hb levels of ≥12 g/dL. Admission and follow-up characteristics were compared across groups. The cohort consisted of 122 adolescents with a mean age of 13.7 ± 1.9 years, 42.7% of whom experienced menstrual irregularity within 2 years of menarche. The mean duration of bleeding was 16 days (range: 10-30 days). Anovulation was identified in 57.8% of patients. Polycystic ovary syndrome was diagnosed in 32 (25%) adolescents, hypothyroidism in 6 (4.7%), uterine structural anomalies in 3 (2.3%), and hyperprolactinemia in 3 (2.3%), 2 of whom had microprolactinoma. One adolescent was diagnosed with von Willebrand disease following a hematological evaluation. Primary care providers must understand normal menstrual cycle patterns and be adept at identifying HMB. Early recognition of the underlying etiology in adolescents facilitates timely diagnosis, helping to prevent severe anemia and hospitalization.
- Open Access
- 30 December 2023
- Published by Atatürk University, Medical Faculty in Atatürk Üniversitesi Tıp Fakültesi Cerrahi Tıp Bilimleri Dergisi
- Vol. 2 (3) , 119-125
Retrospective Evaluation of Patients Followed-Up and Treated for Idiopathic Thrombocytopenic Purpura: A 21-Year Single-Center Experience
Introduction: Primary immune thrombocytopenia (ITP) is an autoimmune disorder that is distinguished by a low platelet count (
- 30 December 2023
- Published by Atatürk University, Medical Faculty in Atatürk Üniversitesi Tıp Fakültesi Cerrahi Tıp Bilimleri Dergisi
- Vol. 2 (3) , 119-125
Open AccessRetrospective Evaluation of Patients Followed-Up and Treated for Idiopathic Thrombocytopenic Purpura: A 21-Year Single-Center Experience
Introduction: Primary immune thrombocytopenia (ITP) is an autoimmune disorder that is distinguished by a low platelet count (
- Open Access
- 1 January 2021
- Published by AVES YAYINCILIK A.Ş. in The Eurasian Journal of Medicine
- Vol. 53 (2) , 118-122
Fluid Rate Is Important As Much As Fluid Tonicity: An Experimental Study
Objective: There is no study evaluating the effect on plasma osmolality of both fluid tonicity and high fluid rate at the same time. The aim of this experimental study was to determine the change in the plasma osmolality by different fluid tonicity and rate, and to suggest the safest and the most appropriate fluids based on the plasma osmolality for medical situations requiring fluid therapy with high or maintenance rates. Materials and methods: The rats were randomly divided into seven groups (six rats in each group): [D5] D5 administered at 100 ml/kg/24h; [D5150] D5 administered at 150 ml/kg/24h; [D5(½)100] D5 0.45% NaCl administered at 100 ml/kg/24h; [D5(½)150] D5 0.45% NaCl administered at 150 ml/kg/24h; [D5(1)100] D5 0.9% NaCl administered at 100 ml/kg/24h; [D5(1)150] D5 0.9% NaCl administered at 150 ml/kg/24h; [Control group] non-treated control rats. Intracardiac blood samples were collected from all the groups at the end of 24 h. Results: [D5(1)150] and [D5(½)100] were the group closest to the control group in terms of both sodium (P = .937; P = .699, respectively) and effective osmolality (P = 1, P = .818, respectively). Conclusion: Our results showed that 0.9% NaCl and 0.45% NaCl solutions might be the safest and the most appropriate fluids to maintain normal plasma osmolality in medical situations requiring fluid therapy with high or maintenance rates, respectively. Cite this article as: Keskin H, Keskin F, Kesin Yildirim Z, Guler MA, Ozturk N, Ozturk Karagoz B, Halici Z. Fluid Rate Is Important As Much As Fluid Tonicity: An Experimental Study. Eurasian J Med 2021; 53(2): 118-22.
- 1 January 2021
- Published by AVES YAYINCILIK A.Ş. in The Eurasian Journal of Medicine
- Vol. 53 (2) , 118-122
Open AccessFluid Rate Is Important As Much As Fluid Tonicity: An Experimental Study
Objective: There is no study evaluating the effect on plasma osmolality of both fluid tonicity and high fluid rate at the same time. The aim of this experimental study was to determine the change in the plasma osmolality by different fluid tonicity and rate, and to suggest the safest and the most appropriate fluids based on the plasma osmolality for medical situations requiring fluid therapy with high or maintenance rates. Materials and methods: The rats were randomly divided into seven groups (six rats in each group): [D5] D5 administered at 100 ml/kg/24h; [D5150] D5 administered at 150 ml/kg/24h; [D5(½)100] D5 0.45% NaCl administered at 100 ml/kg/24h; [D5(½)150] D5 0.45% NaCl administered at 150 ml/kg/24h; [D5(1)100] D5 0.9% NaCl administered at 100 ml/kg/24h; [D5(1)150] D5 0.9% NaCl administered at 150 ml/kg/24h; [Control group] non-treated control rats. Intracardiac blood samples were collected from all the groups at the end of 24 h. Results: [D5(1)150] and [D5(½)100] were the group closest to the control group in terms of both sodium (P = .937; P = .699, respectively) and effective osmolality (P = 1, P = .818, respectively). Conclusion: Our results showed that 0.9% NaCl and 0.45% NaCl solutions might be the safest and the most appropriate fluids to maintain normal plasma osmolality in medical situations requiring fluid therapy with high or maintenance rates, respectively. Cite this article as: Keskin H, Keskin F, Kesin Yildirim Z, Guler MA, Ozturk N, Ozturk Karagoz B, Halici Z. Fluid Rate Is Important As Much As Fluid Tonicity: An Experimental Study. Eurasian J Med 2021; 53(2): 118-22.
- Open Access
- 17 December 2020
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 50 (8) , 1916-1921
Cross-sectional study: long term follow-up care for pediatric cancer survivors in a developing country, Turkey: current status, challenges, and future perspectives
The main purpose of this study is to determine; the current status of long term follow up (LTFU) for childhood cancer survivors and the challenges of LTFU for pediatric cancer survivors at pediatric oncology institutions in Turkey. An e-mailed questionnaire has been sent to directors of 33 pediatric oncology centers registered in the Turkish Pediatric Oncology Group (TPOG).Twenty one of 33 active institutions of the TPOG participated in the study and returned their completed questionnaires. Only 1 of the 21 participating centers had a separate LTFU clinic. The remaining centers had provided LTFU care for chilhood cancer survivors at the pediatric oncology outpatient clinic. Seventeen (80.9%) centers reported difficulty transition from pediatric clinic to adult clinic, 14 centers (66.6%) reported insufficient care providers, 12 (57.1%) centers reported insufficient time and transportation problems. As neglected late effects; 16 (76.1%) centers reported psychosocial and getty job problems, 11 (52.3%) centers reported sexual and cognitive problems. None of the centers have their own LTFU guideline for their daily LTFU practice. This study is the first to gain an overview of the needs of pediatric oncology centers and the gaps in survivorship services in Turkey. The results from this study will help develope a national health care system and national guideline for pediatric cancer survivors.
- 17 December 2020
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 50 (8) , 1916-1921
Open AccessCross-sectional study: long term follow-up care for pediatric cancer survivors in a developing country, Turkey: current status, challenges, and future perspectives
The main purpose of this study is to determine; the current status of long term follow up (LTFU) for childhood cancer survivors and the challenges of LTFU for pediatric cancer survivors at pediatric oncology institutions in Turkey. An e-mailed questionnaire has been sent to directors of 33 pediatric oncology centers registered in the Turkish Pediatric Oncology Group (TPOG).Twenty one of 33 active institutions of the TPOG participated in the study and returned their completed questionnaires. Only 1 of the 21 participating centers had a separate LTFU clinic. The remaining centers had provided LTFU care for chilhood cancer survivors at the pediatric oncology outpatient clinic. Seventeen (80.9%) centers reported difficulty transition from pediatric clinic to adult clinic, 14 centers (66.6%) reported insufficient care providers, 12 (57.1%) centers reported insufficient time and transportation problems. As neglected late effects; 16 (76.1%) centers reported psychosocial and getty job problems, 11 (52.3%) centers reported sexual and cognitive problems. None of the centers have their own LTFU guideline for their daily LTFU practice. This study is the first to gain an overview of the needs of pediatric oncology centers and the gaps in survivorship services in Turkey. The results from this study will help develope a national health care system and national guideline for pediatric cancer survivors.
- 1 August 2020
- Published by Galenos Yayinevi in Güncel Pediatri
- Vol. 18 (2) , 263-275
Assessment of Musculoskeletal Changes and Related Factors in Children with Hemophilia
- 1 August 2020
- Published by Galenos Yayinevi in Güncel Pediatri
- Vol. 18 (2) , 263-275
Assessment of Musculoskeletal Changes and Related Factors in Children with Hemophilia
- 31 July 2019
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 34 (11) , 1763-1767
Clinical features and treatment results in preterm infants with intracardiac thrombus
Thrombus incidence is higher among neonates, especially in preterm infants, due to the associated additional risk factors.The medical recordings of premature infants who had been diagnosed as havin...
- 31 July 2019
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 34 (11) , 1763-1767
Clinical features and treatment results in preterm infants with intracardiac thrombus
Thrombus incidence is higher among neonates, especially in preterm infants, due to the associated additional risk factors.The medical recordings of premature infants who had been diagnosed as havin...
- Open Access
- 1 January 2019
- Published by AVES YAYINCILIK A.Ş. in The Eurasian Journal of Medicine
- Vol. 51 (2) , 112-115
The Comparison of The Efficacy and Safety of Original and Biosimilar Filgrastim in Prevention of Chemotherapy-Induced Neutropenia in Children with Cancer
Objective: In adults and children, the duration of chemotherapy-induced neutropenia and associated complications has decreased because of the prophylactic use of granulocyte colony-stimulating factors (G-CSFs). Biosimilar G-CSFs can play an important role in reducing treatment costs in daily practice. However, some concerns regarding the efficacy and safety of new biosimilar products exist among clinicians. This study compared the efficacy and safety of original and biosimilar filgrastims for the prophylaxis of chemotherapy-induced neutropenia in children. Materials and Methods: Thirty children receiving myelosuppressive chemotherapy were enrolled in this study. Filgrastims (5 μg/kg/day) were subcutaneously administered in Group A (biosimilar, Leucostim®; Dem İlaç) and Group B (original drug, Neupogen®; Roche). Hemoglobin, white blood cell (WBC) count, platelet count, transfusion requirements, duration of hospitalization, and frequency and duration of adverse events including fever, neutropenia, and mucositis were evaluated following 25 treatment cycles in both groups. Results: The hemoglobin value, WBC count, and platelet count on days 1, 5, and 10, and the red blood cell and platelet transfusion requirements, frequency, duration, and severity of mucositis, and durations of fever, febrile neutropenia, and hospitalization were similar in both groups. Although the mean WBC counts on days 1 and 5 were lower in Group A, the difference was statistically insignificant. Conclusion: The biosimilar filgrastim, Leucostim, is as effective and safe as the original drug for prophylaxis of chemotherapy-induced neutropenia in children. Cite this article as: Buyukavci M, Keskin Yildirim Z. The Comparison of The Efficacy and Safety of Original and Biosimilar Filgrastim in Prevention of Chemotherapy-Induced Neutropenia in Children with Cancer. Eurasian J Med 2019; 51(2): 112-5.
- 1 January 2019
- Published by AVES YAYINCILIK A.Ş. in The Eurasian Journal of Medicine
- Vol. 51 (2) , 112-115
Open AccessThe Comparison of The Efficacy and Safety of Original and Biosimilar Filgrastim in Prevention of Chemotherapy-Induced Neutropenia in Children with Cancer
Objective: In adults and children, the duration of chemotherapy-induced neutropenia and associated complications has decreased because of the prophylactic use of granulocyte colony-stimulating factors (G-CSFs). Biosimilar G-CSFs can play an important role in reducing treatment costs in daily practice. However, some concerns regarding the efficacy and safety of new biosimilar products exist among clinicians. This study compared the efficacy and safety of original and biosimilar filgrastims for the prophylaxis of chemotherapy-induced neutropenia in children. Materials and Methods: Thirty children receiving myelosuppressive chemotherapy were enrolled in this study. Filgrastims (5 μg/kg/day) were subcutaneously administered in Group A (biosimilar, Leucostim®; Dem İlaç) and Group B (original drug, Neupogen®; Roche). Hemoglobin, white blood cell (WBC) count, platelet count, transfusion requirements, duration of hospitalization, and frequency and duration of adverse events including fever, neutropenia, and mucositis were evaluated following 25 treatment cycles in both groups. Results: The hemoglobin value, WBC count, and platelet count on days 1, 5, and 10, and the red blood cell and platelet transfusion requirements, frequency, duration, and severity of mucositis, and durations of fever, febrile neutropenia, and hospitalization were similar in both groups. Although the mean WBC counts on days 1 and 5 were lower in Group A, the difference was statistically insignificant. Conclusion: The biosimilar filgrastim, Leucostim, is as effective and safe as the original drug for prophylaxis of chemotherapy-induced neutropenia in children. Cite this article as: Buyukavci M, Keskin Yildirim Z. The Comparison of The Efficacy and Safety of Original and Biosimilar Filgrastim in Prevention of Chemotherapy-Induced Neutropenia in Children with Cancer. Eurasian J Med 2019; 51(2): 112-5.